RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 9, 2021

Primary Completion Date

February 28, 2025

Study Completion Date

August 31, 2025

Conditions
Antiphospholipid SyndromeSystemic Lupus ErythematosusStrokeIschemic StrokeBrain Ischemia
Interventions
DRUG

Rivaroxaban

Oral tablet 15 mg twice daily for 24 months

DRUG

Warfarin

Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months

Trial Locations (6)

Unknown

Epsom and St Helier University Hospitals NHS Trust, Epsom

Barts and the London Hospitals, Barts Health NHS Trust, London

Hammersmith Hospital, Imperial College Healthcare NHS Trust, London

Kings College Hospital NHS Foundation Trust, London

University College Hospitals NHS Foundation Trust, London

Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford

All Listed Sponsors
collaborator

University College London Hospitals

OTHER

collaborator

Barking, Havering and Redbridge University Hospitals NHS Trust

OTHER

collaborator

Hammersmith Hospitals NHS Trust

OTHER

collaborator

Epsom and St Helier University Hospitals NHS Trust

OTHER

collaborator

Barts & The London NHS Trust

OTHER

collaborator

King's College Hospital NHS Trust

OTHER

collaborator

Versus Arthritis (Funder)

UNKNOWN

lead

University College, London

OTHER